News

Mankind Pharma has allotted 80,872 equity shares under ESOP on 19 May 2026. Consequently, the paid up equity share capital has increased to 41,29,09,200 equity shares having face value of Re 1/- each.

Net profit of Mankind Pharma rose 31.75% to Rs 554.35 crore in the quarter ended March 2026 as against Rs 420.77 crore during the previous quarter ended March 2025. Sales rose 11.81% to Rs 3442.93 crore in the quarter ended March 2026 as against Rs 3079.37 crore during the previous quarter ended March 2025.For the full year,net profit declined 3.92% to Rs 1912.93 crore in the year ended March 2026 as against Rs 1990.96 crore during the previous year ended March 2025. Sales rose 16.96% to Rs 14277.64 crore in the year ended March 2026 as against Rs 12207.44 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales3442.933079.37 12 14277.6412207.44 17 OPM %27.0122.19 -25.3424.72 - PBDT905.41746.30 21 3348.613137.55 7 PBT682.33515.43 32 2462.432516.33 -2 NP554.35420.77 32 1912.931990.96 -4 Powered by Capital Market - Live News

Mankind Pharma will hold a meeting of the Board of Directors of the Company on 19 May 2026.

The board of Mankind Pharma at its meeting held on 13 April 2026 has approved the closure/winding-up of Mankind Pharma Lanka, a wholly owned subsidiary (WOS) company incorporated in Sri Lanka, as due to changed regulatory requirements, the anticipated business objectives are no longer viable. There has been no business operations in the aforesaid WOS, and it is not a material subsidiary of the Company.

Mankind Pharma has acquired the brand Rivotril from Roche for the Indian market, with exclusive rights to manufacture, market and distribute the product across the country. Rivotril is the innovator/ reference brand of clonazepam and is widely prescribed for the management of neurological and psychiatric conditions. Often regarded as a Textbook brand in its category with a strong clinical legacy, Rivotril further strengthens Mankind Pharma`s presence in the central nervous system (CNS) therapy segment and complements its existing neuro portfolio. The acquisition builds on Mankind Pharma`s growing focus on chronic therapies, where the company has steadily expanded its presence through new launches, in-licensing partnerships and portfolio additions across key therapeutic areas. Chronic therapies now account for a rising share of the company`s overall business as they continue to scale specialty segments and deepen engagement with specialists and key opinion leaders. Furthermore, the addition of Rivotril, an innovator brand with great recall amongst specialists, will strengthen its CNS portfolio and expand treatment options for patients managing neurological conditions. Powered by Capital Market - Live News